In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from ...
Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...
Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...
In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class ...
Learn how incorporating real-world data at study design can improve feasibility, reduce amendments, and align eligibility ...
New post hoc and pooled analyses from the OASIS 4 trial presented at ObesityWeek 2025 show that oral semaglutide 25 mg improves glycemic control, cardiovascular risk factors, and weight outcomes ...
Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...
In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore ...
Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...
In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...
Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and ...
Takeda has announced the completion of its 7-year, Phase III TIDES clinical trial (NCT02747927) evaluating the dengue vaccine, Qdenga. Along with an exploratory analysis of a booster dose, TIDES data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback